2024
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Larkin K, Pandit-Taskar N, Rowley S, Munshi P, Cook R, Levy M, Lazarus H, Sandmaier B, Pagel J, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. Journal Of Clinical Oncology 2024, jco2302018. PMID: 39298738, DOI: 10.1200/jco.23.02018.Peer-Reviewed Original ResearchEvent-free survivalIntention-to-treat populationIntention-to-treatHazard ratioRR-AMLOverall survivalOlder patientsPhase III open-label trialEvent-free survival HRTreatment-related adverse eventsAllogeneic hematopoietic cell transplantationConventional careIncomplete platelet recoveryOS hazard ratioSecondary end pointsHematopoietic cell transplantationOpen-label trialConventional care groupPretransplant regimenRefractory AMLRelapsed/refractory AMLChemotherapy initiationDismal prognosisPlatelet recoveryCell transplantationAML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Seropian S, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Vusirikala M, Sandmaier B, Pagel J, Desai A, Giralt S. AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s319. DOI: 10.1016/s2152-2650(24)01210-2.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationR/R AMLHematopoietic cell transplantationFollow-upOverall survivalCell transplantationCC patientsCurative allogeneic hematopoietic cell transplantationOlder patientsControlled phase 3 studiesRefractory acute myeloid leukemiaConventional careMedian overall survivalR/R AML patientsMedian follow-upTotal body irradiationBaseline patient characteristicsAcute myeloid leukemiaAnalysis of efficacyOff-target toxicityLong-term survivorsCD45-expressing cellsData cutoffBody irradiationMucositis rates131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes
Foran J, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Nagl N, Brodin P, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Seropian S. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes. Transplantation And Cellular Therapy 2024, 30: s110-s111. DOI: 10.1016/j.jtct.2023.12.174.Peer-Reviewed Original ResearchHematopoietic cell transplantationAllogeneic hematopoietic cell transplantationTP53 mutationsMedian OSOverall survivalPositive PTCell transplantationCC groupDays post-hematopoietic cell transplantationControlled phase 3 studiesEradication of leukemic cellsPost-hematopoietic cell transplantationImprove outcomesConventional careMedian overall survivalTotal body irradiationPhase 3 studyOutcomes of PTPost hoc analysisR/R AMLBody irradiationAML patientsPrimary endpointCurative therapyRelapse rate
2023
131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Choe H, Tomlinson B, Gyurkocza B, Nath R, Seropian S, Litzow M, Abboud C, Stiff P, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Haeuber E, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Koshy N. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML. Blood 2023, 142: 469. DOI: 10.1182/blood-2023-182177.Peer-Reviewed Original ResearchMedian overall survivalAllogeneic hematopoietic cell transplantDurable complete remissionHematopoietic cell transplantOverall survivalR AMLConventional careTP53 mutationsPositive ptsCC groupComplete remissionRelapse rateCell transplantHigh post-transplant relapse ratesInitiation of therapyPhase 3 studyTotal body irradiationHigh relapse rateCRP assessmentEvaluable ptsOlder ptsActive diseaseBaseline characteristicsRefractory AMLBody irradiation
2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic HSCT recipientsAutologous HSCT recipientsHaematopoietic stem cell transplantation recipientsStem cell transplantation recipientsCOVID-19 diagnosisHSCT recipientsNational Cancer InstituteHigh riskAllogeneic HSCTOverall survivalTransplantation recipientsCOVID-19Cancer InstituteCox proportional hazards modelAggressive treatment measuresSurvival 30 daysObservational cohort studyMarrow Transplant ResearchPoor overall survivalAge 50 yearsOverall survival probabilityPlasma cell disordersMonths of transplantationProportional hazards modelNational Institute
2020
Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patientsClinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphomaAllogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience
Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience. Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.Peer-Reviewed Original ResearchT-cell lymphomaProgression-free survivalTransplant related mortalityCumulative incidenceOverall survivalAutologous stem cell transplant consolidationOne-year progression-free survivalT-cell-rich B-cellT-cell lymphoma typesCutaneous T-cell lymphomaLong-term prospective studiesT-cell lymphoma subtypesPost-transplant relapseReduced intensity regimensTBI/CYHigh-dose chemotherapyNK T cellsSingle-center experienceOverall favorable outcomeKaplan-Meier analysisPretransplant conditioning regimenAllogeneic stem cellsPeripheral T-cell lymphoma subtypesAutologous SCTChronic GVHD
2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.Peer-Reviewed Original ResearchConceptsImmune activationAntitumor effectsNK cellsT cellsMore frequent adverse eventsClinical antitumor effectsFrequent adverse eventsNatural killer cellsIntermittent dosing strategyDirect antitumor effectsExpression of cytokinesT cell activationGreater tumor reductionPomalidomide/Coinhibitory receptorsAdverse eventsClinical responseOverall survivalKiller cellsPharmacodynamic effectsImmunomodulatory effectsMultiple myelomaTumor reductionIntermittent dosingPharmacodynamic analysis
2008
Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.
Maggiore R, Cooper D, Foss F, Shlomchik W, Seropian S. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2008, 112: 2216. DOI: 10.1182/blood.v112.11.2216.2216.Peer-Reviewed Original ResearchAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationNon-relapse mortalityUnrelated donor allogeneic hematopoietic stem cell transplantationDonor allogeneic hematopoietic stem cell transplantationKaplan-Meier estimatesStem cell transplantationAcute GVHDSirolimus groupThrombotic microangiopathyOverall survivalHigh-resolution HLA typingAllele-level typingChronic GVHDProphylactic regimenRenal dysfunctionGraft failureDisease recurrenceCell transplantationHLA AHLA-DRB1HLA typingLate-onset acute GvHDPeripheral blood stem cellsLess chronic GVHD
2003
Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma
Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplantation 2003, 32: 763-769. PMID: 14520419, DOI: 10.1038/sj.bmt.1704233.Peer-Reviewed Original ResearchConceptsPeripheral blood stem cellsNon-Hodgkin lymphomaNonrelapse mortalityAutologous transplantAllogeneic peripheral blood stem cell transplantationPoor-prognosis non-Hodgkin's lymphomaPeripheral blood stem cell transplantationBlood stem cell transplantationHost disease (GVHD) prophylaxisMini-dose methotrexateLow-grade histologyReduced-intensity conditioningStem cell transplantationBlood stem cellsHigh-grade lymphomaAbnormal organ functionAblative regimensLymphoma effectPrevious transplantAdditional therapyIntravenous busulfanPost transplantPotent graftAllogeneic transplantsOverall survival
2000
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease
Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineDisease-Free SurvivalEtoposideFemaleHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansL-Lactate DehydrogenaseMaleMelphalanMiddle AgedPrognosisRecurrenceTransplantation, AutologousConceptsProgression-free survivalHigh-dose BEAM chemotherapyPeripheral blood progenitor cellsAutologous PBPC transplantationTime of transplantationPrimary refractoryHodgkin's diseaseHigh-dose BEAMBEAM chemotherapyPBPC transplantationOverall survivalAutologous peripheral blood progenitor cell transplantationAutologous peripheral blood progenitor cellsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationSatisfactory progression-free survivalSevere non-hematologic toxicityWorse progression-free survivalPoor progression-free survivalAutologous PBPC infusionNon-hematologic toxicitiesTransplant-related complicationsConsecutive adult patientsElevated lactate dehydrogenaseRelapse/progression